The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Jeffrey Hubbell and Melody Swartz.
Connection Strength

6.980
  1. Trojan horses for immunotherapy. Nat Nanotechnol. 2019 03; 14(3):196-197.
    View in: PubMed
    Score: 0.708
  2. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin Immunol. 2008 Apr; 20(2):147-56.
    View in: PubMed
    Score: 0.327
  3. Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity. Sci Adv. 2023 12; 9(48):eadh9879.
    View in: PubMed
    Score: 0.246
  4. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022 10 07; 8(40):eabn3777.
    View in: PubMed
    Score: 0.227
  5. Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity. ACS Cent Sci. 2022 Oct 26; 8(10):1435-1446.
    View in: PubMed
    Score: 0.227
  6. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat Biomed Eng. 2022 07; 6(7):819-829.
    View in: PubMed
    Score: 0.221
  7. SARS-CoV-2 infection induces cross-reactive autoantibodies against angiotensin II. medRxiv. 2021 Nov 02.
    View in: PubMed
    Score: 0.213
  8. Overcoming transport barriers to immunotherapy. Drug Deliv Transl Res. 2021 12; 11(6):2273-2275.
    View in: PubMed
    Score: 0.213
  9. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. Biomaterials. 2021 11; 278:121159.
    View in: PubMed
    Score: 0.212
  10. Lymph Node-Targeted Synthetically Glycosylated Antigen Leads to Antigen-Specific Immunological Tolerance. Front Immunol. 2021; 12:714842.
    View in: PubMed
    Score: 0.211
  11. Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. ACS Cent Sci. 2021 Aug 25; 7(8):1368-1380.
    View in: PubMed
    Score: 0.209
  12. Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity. bioRxiv. 2021 Apr 08.
    View in: PubMed
    Score: 0.205
  13. Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas. Sci Adv. 2021 03; 7(13).
    View in: PubMed
    Score: 0.204
  14. Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models. Arthritis Rheumatol. 2021 05; 73(5):769-778.
    View in: PubMed
    Score: 0.204
  15. Publisher Correction: Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat Biomed Eng. 2020 Nov; 4(11):1117.
    View in: PubMed
    Score: 0.199
  16. Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat Biomed Eng. 2021 05; 5(5):387-398.
    View in: PubMed
    Score: 0.198
  17. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat Biomed Eng. 2020 05; 4(5):531-543.
    View in: PubMed
    Score: 0.191
  18. Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019 12; 5(12):eaay1357.
    View in: PubMed
    Score: 0.187
  19. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019 04 10; 11(487).
    View in: PubMed
    Score: 0.178
  20. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nat Mater. 2019 02; 18(2):175-185.
    View in: PubMed
    Score: 0.175
  21. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411.
    View in: PubMed
    Score: 0.170
  22. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. Virology. 2017 12; 512:161-171.
    View in: PubMed
    Score: 0.160
  23. Local induction of lymphangiogenesis with engineered fibrin-binding VEGF-C promotes wound healing by increasing immune cell trafficking and matrix remodeling. Biomaterials. 2017 07; 131:160-175.
    View in: PubMed
    Score: 0.155
  24. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J Allergy Clin Immunol. 2017 Nov; 140(5):1339-1350.
    View in: PubMed
    Score: 0.155
  25. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses. Vaccine. 2016 05 05; 34(21):2453-2459.
    View in: PubMed
    Score: 0.144
  26. A Cationic Micelle Complex Improves CD8+ T Cell Responses in Vaccination Against Unmodified Protein Antigen. ACS Biomater Sci Eng. 2016 Feb 08; 2(2):231-240.
    View in: PubMed
    Score: 0.142
  27. VEGFR-3 neutralization inhibits ovarian lymphangiogenesis, follicle maturation, and murine pregnancy. Am J Pathol. 2013 Nov; 183(5):1596-1607.
    View in: PubMed
    Score: 0.121
  28. Engineering approaches to immunotherapy. Sci Transl Med. 2012 Aug 22; 4(148):148rv9.
    View in: PubMed
    Score: 0.113
  29. Materials engineering for immunomodulation. Nature. 2009 Nov 26; 462(7272):449-60.
    View in: PubMed
    Score: 0.093
  30. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006 Dec; 27(12):573-9.
    View in: PubMed
    Score: 0.075
  31. Membrane-localized neoantigens predict the efficacy of cancer immunotherapy. Cell Rep Med. 2023 08 15; 4(8):101145.
    View in: PubMed
    Score: 0.060
  32. Engineering Targeting Materials for Therapeutic Cancer Vaccines. Front Bioeng Biotechnol. 2020; 8:19.
    View in: PubMed
    Score: 0.047
  33. Growth factors with enhanced syndecan binding generate tonic signalling and promote tissue healing. Nat Biomed Eng. 2020 04; 4(4):463-475.
    View in: PubMed
    Score: 0.046
  34. Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. Front Immunol. 2019; 10:294.
    View in: PubMed
    Score: 0.044
  35. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 08; 9(415).
    View in: PubMed
    Score: 0.040
  36. Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses. Biomaterials. 2017 07; 132:48-58.
    View in: PubMed
    Score: 0.039
  37. Primary Human and Rat ß-Cells Release the Intracellular Autoantigens GAD65, IA-2, and Proinsulin in Exosomes Together With Cytokine-Induced Enhancers of Immunity. Diabetes. 2017 02; 66(2):460-473.
    View in: PubMed
    Score: 0.038
  38. Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice. Sci Rep. 2015 Sep 21; 5:14274.
    View in: PubMed
    Score: 0.035
  39. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. Cancer Immunol Immunother. 2015 Aug; 64(8):1033-46.
    View in: PubMed
    Score: 0.034
  40. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science. 2014 Feb 21; 343(6173):885-8.
    View in: PubMed
    Score: 0.031
  41. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014 May; 2(5):436-47.
    View in: PubMed
    Score: 0.031
  42. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013 Dec 03; 110(49):19902-7.
    View in: PubMed
    Score: 0.031
  43. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials. 2014 Jan; 35(2):814-24.
    View in: PubMed
    Score: 0.030
  44. The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165. Biomaterials. 2013 Aug; 34(24):5958-68.
    View in: PubMed
    Score: 0.030
  45. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS One. 2013; 8(4):e61646.
    View in: PubMed
    Score: 0.029
  46. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. Biomaterials. 2013 Jun; 34(17):4339-46.
    View in: PubMed
    Score: 0.029
  47. Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. Vaccine. 2012 Dec 14; 30(52):7541-6.
    View in: PubMed
    Score: 0.028
  48. Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization. Acta Biomater. 2012 Sep; 8(9):3210-7.
    View in: PubMed
    Score: 0.028
  49. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials. 2012 Sep; 33(26):6211-9.
    View in: PubMed
    Score: 0.028
  50. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A. 2011 Nov 01; 108(44):E989-97.
    View in: PubMed
    Score: 0.026
  51. PEG-b-PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA: tumor immunotoxicity in B16F10 melanoma. Biomaterials. 2011 Dec; 32(36):9839-47.
    View in: PubMed
    Score: 0.026
  52. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. J Control Release. 2011 Dec 10; 156(2):154-60.
    View in: PubMed
    Score: 0.026
  53. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine. 2011 Sep 16; 29(40):6959-66.
    View in: PubMed
    Score: 0.026
  54. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials. 2011 Mar; 32(8):2194-203.
    View in: PubMed
    Score: 0.025
  55. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine. 2011 Jan 17; 29(4):804-12.
    View in: PubMed
    Score: 0.025
  56. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine. 2010 Nov 23; 28(50):7897-906.
    View in: PubMed
    Score: 0.025
  57. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007 Oct; 25(10):1159-64.
    View in: PubMed
    Score: 0.020
  58. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006 May 01; 112(1):26-34.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.